Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying
Alleles
Antipsychotic Agents
/ adverse effects
Cytochrome P-450 CYP2D6
/ genetics
Drug-Related Side Effects and Adverse Reactions
/ diagnosis
Genetic Association Studies
Genetic Variation
Genotype
Humans
Male
Middle Aged
Pharmacogenetics
Pharmacogenomic Variants
Phenotype
Quetiapine Fumarate
/ administration & dosage
Severity of Illness Index
CYP2D6
CYP3A4
adverse drug reaction
antipsychotics
depression
neuroleptics
pharmaceutical care
pharmacogenetics
psychiatry
quetiapine
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
17 Jun 2021
17 Jun 2021
Historique:
received:
20
05
2021
revised:
11
06
2021
accepted:
14
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
20
7
2021
Statut:
epublish
Résumé
We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and 400 mg. The extensive hepatic metabolism of quetiapine is mainly attributed to cytochrome P450 3A4 (CYP3A4). However, there is recent evidence supporting the idea of CYP2D6 playing a role in the clearance of the quetiapine active metabolite norquetiapine. Interestingly, both patients we are reporting of are carriers of the
Identifiants
pubmed: 34204223
pii: ijms22126480
doi: 10.3390/ijms22126480
pmc: PMC8233787
pii:
doi:
Substances chimiques
Antipsychotic Agents
0
Quetiapine Fumarate
2S3PL1B6UJ
Cytochrome P-450 CYP2D6
EC 1.14.14.1
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Stiftung zur Förderung des pharmazeutischen Nachwuchses in Basel, Basel, Switzerland
ID : not applicable
Références
Arch Gen Psychiatry. 1997 Jun;54(6):549-57
pubmed: 9193196
Br J Pharmacol. 2016 Jan;173(1):155-66
pubmed: 26436896
Ther Drug Monit. 2015 Apr;37(2):256-61
pubmed: 25254417
Drug Metab Dispos. 2001 Aug;29(8):1102-9
pubmed: 11454728
Pharmacogenomics J. 2020 Oct 17;:
pubmed: 33070160
Drug Metab Dispos. 2012 Sep;40(9):1778-84
pubmed: 22688609
Arch Gen Psychiatry. 2000 Jun;57(6):553-9
pubmed: 10839333
Pharmacopsychiatry. 2004 Mar;37 Suppl 1:S39-45
pubmed: 15052513
J Clin Psychopharmacol. 2005 Jun;25(3):226-9
pubmed: 15876900
Ther Drug Monit. 2011 Apr;33(2):222-6
pubmed: 21383647
J Clin Psychopharmacol. 2007 Feb;27(1):28-34
pubmed: 17224709
Pharmacogenomics. 2020 Nov;21(16):1145-1150
pubmed: 33124517
Pharmacopsychiatry. 2004 Mar;37 Suppl 1:S46-53
pubmed: 15052514
Psychopharmacology (Berl). 1998 Jan;135(2):119-26
pubmed: 9497016
Pharmgenomics Pers Med. 2021 Feb 19;14:279-286
pubmed: 33642872
Clin Pharmacol Ther. 2011 May;89(5):662-73
pubmed: 21412232
Neuropsychopharmacology. 2008 Sep;33(10):2303-12
pubmed: 18059438
Br J Clin Pharmacol. 2006 Jan;61(1):58-69
pubmed: 16390352
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
Clin Pharmacokinet. 2001;40(7):509-22
pubmed: 11510628
J Clin Med. 2020 Sep 07;9(9):
pubmed: 32906709
Psychopharmacology (Berl). 1993;112(2-3):285-92
pubmed: 7871032
Mod Probl Pharmacopsychiatry. 1974;7(0):151-69
pubmed: 4412100
Swiss Med Wkly. 2013 Jul 02;143:w13772
pubmed: 23821346